TerraPower Isotopes to Establish Major cGMP Facility for Actinium-225 in Philadelphia

In a significant development for the radiopharmaceutical industry, TerraPower Isotopes® (TPI®) has announced its decision to build a new manufacturing facility focused on current Good Manufacturing Practices (cGMP) for actinium-225 (Ac-225) in the Bellwether District of Philadelphia, Pennsylvania. This facility is set to enhance TPI's production capacity by an astounding twenty times, solidifying its position as a leading global distributor of Ac-225, an isotope that is making strides in cancer treatment.

The announcement was made on March 17, 2026, marking a pivotal moment for TPI as it complements the expansion of its existing operations in Everett, Washington. Chris Levesque, president and CEO of TerraPower, highlighted the company's mission to bring innovative technologies to the market that can significantly improve lives, stating that this facility will increase access to this crucial isotope for researchers and drug developers involved in advancing cancer treatments. The construction is expected to take several years, with cGMP production of Ac-225 commencing in 2029.

Scott Claunch, president of TPI, emphasized the importance of this new facility in meeting the growing demand for Ac-225, which has been gaining recognition as an essential component of next-generation targeted alpha therapies. Ac-225 has already been utilized in various human clinical trials across the globe, showing promise in precision medicine for cancer treatment.

The decision to establish the facility in Philadelphia was the result of a thorough evaluation process by TPI, reviewing over 350 potential sites across the United States and conducting 49 site visits in 8 metropolitan areas. The selected Bellwether District is strategically situated to provide the necessary scale, proximity to critical infrastructure, and access to a robust life sciences ecosystem that will be beneficial for both TPI and the broader radiopharmaceutical sector.

Local leaders have lauded this initiative, acknowledging that TPI's presence in Philadelphia will augment the city's reputation as a hub for health, science, and technology. Kevin B. Mahoney, CEO of the University of Pennsylvania Health System, remarked that TPI’s establishment brings new expertise and momentum to the region's dynamic research community, helping to tackle pressing global health challenges.

Moreover, Sumit Verma, co-founder of Orchestra Life Sciences, emphasized the significance of the facility in reinforcing Philadelphia's role as a premier location for advanced therapies and innovation in nuclear medicine and radiopharmaceutical development. This aligns perfectly with the mission of TPI, which was founded with the goal of utilizing nuclear science to address global challenges.

Jaap Duiker, Managing Director at Von Gahlen, expressed his congratulations to TPI on this milestone, reinforcing that the new facility is a critical step in strengthening the infrastructure needed to accelerate innovations in cancer treatment through targeted alpha therapies.

In conclusion, the establishment of the new cGMP manufacturing facility marks a critical step towards improving the availability of actinium-225, which has increasingly become an indispensable resource in the treatment of cancer. As the radiopharmaceutical industry continues to evolve, TerraPower Isotopes is poised to play a significant role in shaping the future of targeted cancer therapies, ultimately supporting a shift towards more effective and precise medical interventions. Keep an eye on developments as the construction progresses and production is projected to commence in 2029.